Showing results (1911-1920 of 2,453) with videos related to

Sort By:
Pageof 246
Clinical and Translational Science|June 1, 2020
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, et al.
Clinical and Translational Science|August 25, 2021
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modelingFelix Huth, Hilmar Schiller, Yi Jin, et al.
Clinical and Translational Science|May 1, 2021
Immune response profiling in patients with traumatic injuries associated with alcohol ingestionAdam W Breslin, Alexander T Limkakeng, Elizabeth Silvius, et al.
Clinical and Translational Science|August 18, 2021
An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinomaAstrid De Meulenaere, Tijl Vermassen, David Creytens, et al.
Clinical and Translational Science|August 23, 2021
A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performanceShengfang Su, Gary Kay, Thomas Hochadel, et al.
Clinical and Translational Science|May 22, 2015
Impact of Professional Student Mentored Research Fellowship on Medical Education and Academic Medicine Career PathChristopher James Areephanthu, Raevti Bole, Terry Stratton, et al.
Clinical and Translational Science|August 20, 2016
Matrix Metalloproteinase-1 Expression in Women With and Without Pelvic Organ Prolapse: A Systematic Review and Meta-analysisY Feng, Y Wang, B Yan, et al.
Clinical and Translational Science|April 9, 2020
Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation PatientsRobyn Konicki, Daniel Weiner, J Herbert Patterson, et al.
Clinical and Translational Science|June 17, 2020
Serum Metabolomic Profiles Associated With Untreated Metabolic Syndrome Patients in the Chinese PopulationYuanyuan Li, Yongfa Wang, Yaodong Zhuang, et al.
Clinical and Translational Science|April 22, 2020
Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR MutationsYuichiro Takeda, Naoki Ishizuka, Kazumi Sano, et al.
Pageof 246